Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.
Its DROPZYLLA™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. Combined with our microfluidic high throughput single cell-based functional screening system this leads to entirely new possibilities in immune repertoire analysis and antibody discovery.
The business strategy of Memo Therapeutics is the discovery of therapeutic antibody candidates and target discovery for antibody and vaccine development. DROPZYLLA™ is deployed in proprietary antibody discovery programs and is made available in collaborations e.g. for screening of CAR-T; TCR-T or bi-specific antibodies.
Its DROPZYLLA™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. Combined with our microfluidic high throughput single cell-based functional screening system this leads to entirely new possibilities in immune repertoire analysis and antibody discovery.
The business strategy of Memo Therapeutics is the discovery of therapeutic antibody candidates and target discovery for antibody and vaccine development. DROPZYLLA™ is deployed in proprietary antibody discovery programs and is made available in collaborations e.g. for screening of CAR-T; TCR-T or bi-specific antibodies.
Location: Switzerland
Employees: 11-50
Total raised: $106.22M
Founded date: 2012
Investors 5
| Date | Name | Website |
| - | Vesalius B... | vesaliusbi... |
| - | Verve Vent... | verve.vc |
| 12.06.2024 | Ysios Capi... | ysioscapit... |
| - | Adjuvant C... | adjuvantca... |
| - | VentureLab | venturelab... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 07.05.2024 | - | $22.07M | - |
| 02.11.2023 | Series C | $27.64M | - |
| 16.02.2022 | Series B | $40.01M | - |
| 06.11.2020 | Series B | $16.51M | - |
Mentions in press and media 46
| Date | Title | Description |
| 09.02.2026 | Memo Therapeutics enters into a collaboration with CSL | Under the Collaboration and Option Agreement, Schlieren-based Memo Therapeutics AG (MTx) will develop recombinant polyclonal IgG products, leveraging its proprietary DROPZYLLA® technology platform for cloning human antibody repertoires and... |
| 23.12.2025 | Regulatory approval and a milestone payment for Swiss biotechs | The European Commission has granted orphan designation in the European Union (EU) for Memo Therapeutics’ potravitug, a highly potent human BK polyomavirus (BKPyV)-neutralizing antibody for the treatment of BKPyV infection in kidney transpl... |
| 07.11.2025 | Development milestones and financing for biotech companies | Timeline, a longevity biotech company behind Mitopure® (Urolithin A) — a postbiotic that stimulates mitophagy, the body’s cellular recycling process critical for mitochondrial and metabolic health — has published a new clinical study on im... |
| 02.09.2025 | Regulatory milestones and clinical progress for Swiss biotechs | TOLREMO therapeutics AG, a Swiss biotech startup redefining cancer treatment by targeting non-oncogene addiction, has obtained two Fast Track designations from the U.S. Food and Drug Administration (FDA) for its lead candidate, TT125-802 f... |
| 23.07.2025 | Three biotechs on the verge of launching potential treatments | Berlin Heals, a pioneer in bioelectric medicine for the treatment of heart failure, announced the publication of a new peer-reviewed study titled "Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in... |
| 04.11.2024 | Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer | PRESS RELEASE Frits is an industry veteran with a proven track record in nephrology drug development, including the successful development of Velphoro® and Ferinject® at Vifor Pharma Schlieren / Zurich, Switzerland, 4 November, 2024 – Memo ... |
| 01.11.2024 | Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients | Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that the las... |
| 01.11.2024 | Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients | Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that the las... |
| 03.10.2024 | European VC firm Kurma closes first $154M of largest planned fund, eyes up to 20 biotech investments | European VC firm Kurma Partners has unveiled its latest biotech fund, with 140 million euros ($154 million) raised so far and three biotech beneficiaries already named. Kurma plans to raise a total of 250 million euros ($276 million) for th... |
| 27.08.2024 | Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy | PRESS RELEASE Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy Seasoned commercial leader with significant international experience Joins ahead of lead development candidate Potravitug entering Phase III trial Schlieren / Z... |
Show more